|
|
Immutep Limited (NASDAQ: IMMP) |
|
Price: $1.7300
$0.08 
4.848%
|
| Day's High:
| $1.81
| Week Perf:
| 6.79 %
|
| Day's Low: |
$ 1.67 |
30 Day Perf: |
-5.98 % |
| Volume (M): |
48 |
52 Wk High: |
$ 3.34 |
| Volume (M$): |
$ 83 |
52 Wk Avg: |
$2.13 |
| Open: |
$1.70 |
52 Wk Low: |
$1.32 |
|
|
| Market Capitalization (Millions $) |
2,076 |
| Shares
Outstanding (Millions) |
1,200 |
| Employees |
40 |
| Revenues (TTM) (Millions $) |
8 |
| Net Income (TTM) (Millions $) |
-43 |
| Cash Flow (TTM) (Millions $) |
123 |
| Capital Exp. (TTM) (Millions $) |
0 |
Immutep Limited
Immutep Limited is a biotechnology company based in Sydney, Australia. The company focuses on developing immunotherapeutic products for the treatment of cancer and autoimmune diseases. Immutep's main product candidate is called eftilagimod alpha (efti), which is designed to stimulate the immune system to fight cancer cells.
Efti is being investigated in various clinical trials for the treatment of different types of cancer, including breast, lung, and renal cell cancers. The company also collaborates with pharmaceutical companies to develop combination therapies using efti and other immune checkpoint inhibitors.
Immutep is known for its expertise in the field of antigen-presenting cell biology and its ability to modulate the immune response. The company's research and development efforts are aimed at improving the efficacy of immunotherapies and advancing the understanding of immune system interactions.
In addition to its clinical development programs, Immutep is also actively engaged in strategic collaborations and licensing agreements to further advance its product pipeline. The company has a global presence and collaborates with academic institutions, healthcare organizations, and industry leaders to accelerate the development of novel immunotherapies.
Company Address: Level 32, Australia Square Sydney 2000
Company Phone Number: 8315 7003 Stock Exchange / Ticker: NASDAQ IMMP
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Clinical Study
Published Sun, Dec 29 2024 2:14 PM UTC
Immutep Limited (ASX: IMM; NASDAQ: IMMP), a notable player in the field of biotechnology focusing on LAG-3 immunotherapies, recently announced encouraging initial safety data from its Phase I clinical trial evaluating IMP761. This first-in-human study, which is both placebo-controlled and double-blind, marks a significant milestone for the company as it explores novel therap...
|
| Immutep Limited
Immutep Limited: A Beacon of Innovation Amidst Financial DeficitsAs I sift through the latest financial results from Immutep Limited, it?s clear that this pioneering biotechnology company, known for its work in immunotherapy for cancer, is a study in contrasts. On the surface, the numbers might seem alarming: a loss of $0.04 per share remains unchanged from last year and shows a stark deviation from the previous quarter's break-even point. Furthermore, a net deficit of $42.7 million points to increasing financial pressures compared to the previous year's loss of $39.9 million. Yet, beneath these seemingly dire figures lies a different narrative?one underscored by noteworthy revenue growth and profound implications for the healthcare sector.In the most recent fiscal period, Immutep?s revenue surged by an impressive 50.7%, reaching $7.84 million from $5.20 million in the same quarter a year before. This growth stands in stark contrast with many of its peers in the Major Pharmaceutical Preparations sector, who averaged a modest revenue uptick of just 5.17% during the fourth quarter of 2024. The fact that Immutep has managed this kind of leap highlights the company?s ability to capture interest and funding, even as the broader market flounders.
|
| Stocks on the Move
Published Wed, Jul 3 2024 5:29 PM UTC
Immutep Limited, a pioneering biotechnology company focused on developing effective immunotherapy treatments for cancer, is making waves in the medical field with its ground-breaking research and clinical results. Despite a slump in the market, Immutep s cutting-edge innovations continue to captivate investors and healthcare professionals alike.Recent news reveals that Immut...
|
| Stocks on the Move
Published Fri, Jun 28 2024 5:09 AM UTC
Immutep Ltd (ASX: IMM), an Australian healthcare company specializing in the development of novel LAG-3 immunotherapies, has witnessed a significant decline in its stock price over the past few days. The market reaction, however, presents a compelling buying opportunity, according to market analysts. This article aims to provide an analysis of the recent articles surroundin...
|
| Immutep Limited
Immutep Limited, an innovative biotechnology company, experienced a significant increase in loss for the financial quarter ending June 30, 2023. This rise in loss per share was mainly attributed to declining orders, which led to a drop in revenue. Immutep Limited also reported a stark contrast to the wider Major Pharmaceutical Preparations sector, which showed a rise in revenue during the same period.
Financial Performance Analysis:
During the three months ending June 30, 2023, Immutep Limited witnessed an increase in loss per share from $-0.04 to $-0.04. Additionally, the company's revenue declined by 23.053%, reaching $5.20 million compared to $6.76 million in the corresponding period last year. These numbers indicate a challenging quarter for the company, primarily due to declining orders impacting its financial performance.
|
| Per Share |
Current |
| Earnings (TTM) |
-0.04 $ |
| Revenues (TTM) |
0.01 $
|
| Cash Flow (TTM) |
0.1 $ |
| Cash |
0.13 $
|
| Book Value |
0.16 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.04 $
|
| Revenues (TTM) |
0.01 $ |
| Cash Flow (TTM) |
0.1 $ |
| Cash |
0.13 $
|
| Book Value |
0.16 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| Immunotherapy |
|
 49.01 % |
of total Revenue |
| Unallocated |
|
50.98 % |
of total Revenue |
|
|
